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BACKGROUND: This study assessed the impact of human epidermal growth factor receptor 2 (HER2) status on the outcomes in an
unselected population of breast cancer patients who did not receive HER2-targeted therapy.
METHODS: HER2 status by immunohistochemistry and fluorescence in situ hybridisation was compared with clinicopathological data,
overall survival (OS) and disease-free survival (DFS) for all patients presenting with breast cancer over 3 years.
RESULTS: In 865 patients (median follow up 6.02 years), HER2 positivity was identified in 13.3% of all cancers and was associated
with higher tumour grade (Po10
 8), lymphovascular invasion (Po0.001) and axillary nodal metastasis (P¼0.003). There was a
negative association with oestrogen-receptor (ER) and progesterone-receptor expression (Po10
 8), but the majority (57%)
of HER2þtumours were ERþHER2 positivity was associated with poorer OS (P¼0.0046) and DFS (P¼0.0001) confined to the
lymph node-positive (LNþ) and ERþ subgroups.
CONCLUSION: HER2-positive cancers were less common in this population-based cohort than most selected series. The association of
HER2 positivity with poor prognosis was confined to the ERþ and LNþ subgroups. The survival deficit for the 7.5% of patients with
ERþ/HER2þ cancer compared with ERþ/HER2– patients points to a significant subgroup of women who may not (currently) be
considered for HER2-directed therapy.
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The human epidermal growth factor receptor 2 (HER2) gene is the
human homologue of the rat oncogene neu, originally identified as
a result of transformation of mouse fibroblasts by DNA derived
from a chemically induced rat neuroblastoma (Shih et al, 1981).
This gene was shown to be homologous to the avian erythro-
blastosis virus (v-erb B) and the cellular epidermal growth factor
receptor (EGFR) (Schechter et al, 1984, 1985). An EGFR-related
gene was subsequently shown to be amplified in a human breast
cancer cell line and named HER2 (King et al, 1985). HER2 is a
member of a type 1 trans-membrane protein family characterised
by an extracellular ligand-binding domain, a trans-membrane
domain and an intracellular tyrosine kinase domain. Ligand
binding results in a conformational change causing tyrosine kinase
activation and intracellular signalling. HER2 has no known ligand
and probably operates by way of heterodimerisation with HER3
(Moasser, 2007). HER2 over-expression has been shown to result
in increased invasiveness and tumourigenicity as well as increased
proliferation, tumourigenic growth and transformed characteris-
tics (Moasser, 2007).
The significance of HER2 in human breast cancer was first
identified when gene amplification was described in 30% of
invasive tumours (Slamon et al, 1987) and further studies showed
that this amplification is commonly associated with elevated
HER2 mRNA and protein levels (Slamon et al, 1989) with the
oncogenic effects of HER2 in human cancer being the result of
gene amplification rather than mutation (Slamon et al, 1987).
In early studies, HER2 gene amplification was shown to predict
poor prognosis (overall survival (OS) and disease-free survival
(DFS)) and, furthermore, HER2 amplification was an independent
prognostic variable superior to all other known variables except
nodal metastasis (Slamon et al, 1987, 1989). The prognostic
influence of HER2 positivity was shown in the node-positive (but
not in node-negative) patient group (Slamon et al, 1987, 1989).
Subsequent studies have presented conflicting data regarding
the significance of HER2 positivity in relation to nodal metastasis.
Some suggest that HER2 amplification (Seshadri et al, 1993; Chia
et al, 2008), over-expression (Press et al, 1993; Menard et al, 2008)
or a combination of both (Chia et al, 2008; Curigliano et al, 2009;
Gonzalez-Angulo et al, 2009; Tovey et al, 2009) do predict outcome
in node-negative patients, whereas a large pooled analysis of
similar studies (selected on the basis of sufficient population size
and follow-up) suggest that they do not (Mirza et al, 2002). Some
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sreasons for the conflicting evidence include patient selection, short
follow-up, markedly differing methodologies for the assessment of
HER2 amplification and over-expression (Ravdin and Chamness,
1995) and that in some studies ‘prognosis’ refers to DFS or relapse-
free survival and not overall or breast cancer-specific survival
(Curigliano et al, 2009; Gonzalez-Angulo et al, 2009).
HER2-targeted therapy showed clinical utility through trials
with trastuzumab, which showed increased time to progression in
advanced disease (Slamon et al, 2001), increased frequency of
complete pathological response in the neo-adjuvant setting
(Buzdar et al, 2005) and prolonged DFS and OS in the adjuvant
setting (Piccart-Gebhart et al, 2005; Romond et al, 2005; Smith
et al, 2007; Perez and Baweja, 2008). Subsequently, further
clinically useful therapies such as lapatinib have emerged (Perez
and Baweja, 2008). Whereas trastuzumab may also be active in
some HER2– disease; the underlying mechanism for this is unclear
(Paik et al, 2008) and the focus remains on discerning which
patients with HER2þ cancers might benefit from and should
receive HER2-directed therapy.
The published frequency of HER2 amplification ranges between
8 and 30% (Seshadri et al, 1993; Press et al, 1997; Ellis et al, 2005;
Crowe et al, 2006; Park et al, 2006; Frogne et al, 2009; Sauter et al,
2009; Tovey et al, 2009) and protein over-expression even more
widely, between 2 and 50% (Slamon et al, 1989; Koeppen et al,
2001; Sauter et al, 2009) although, again, these studies differ in the
methodologies used and the populations studied. The true
frequency of HER2 amplification may be of the order of 15–17%
in a less selected population (Walker et al, 2008) and a recent
review of HER2 testing suggests fluorescence in situ hybridisation
(FISH) rather than immunohistochemistry (IHC) testing could be
considered as the primary clinical test (Sauter et al, 2009).
However, such a reliance on FISH testing alone can risk missing
patients who overexpress HER2 but are not amplified on FISH.
Here we report the first population-based study, which has
examined an unselected, consecutive series of invasive breast cancers
presenting to a single cancer centre over a 3-year period. The aim of
the study was to identify the true prevalence of HER2þ breast
cancer and to explore the therapeutic and clinical implications in a
population who had not received HER2-targeted therapy.
MATERIALS AND METHODS
Study population
The patients in this study comprise an unselected, consecutive
series of 920 patients with invasive breast cancer presenting to the
Regional Cancer Centre between 1 June 2000 and 30 June 2003.
This represents 3 full years and the start of the study corresponds
with the point at which HER2 analysis of all breast cancers became
routine practice in Tayside, Scotland.
The Cancer Centre treats all screen detected and symptomatic
breast cancer patients from a defined geographic area (Tayside)
with all patient records (including pathology and follow-up)
maintained within one institution ensuring a complete database.
The population within this region is relatively homogenous,
Caucasian and stable in terms of movement into and out of the
region, ensuring good follow-up and high levels of data complete-
ness. The clinical data recorded included age at diagnosis, sex,
mode of referral, final surgical treatment and adjuvant therapy.
All patients undergoing curative surgery had adjuvant therapy
(including chemotherapy) as per the Scottish Intercollegiate
Guidelines Network (SIGN) guidelines (SIGN, 2005). Data on
adjuvant chemotherapy and endocrine therapy were obtained
from the oncology database. No patients received therapy directed
at HER2 or other members of the EGFR family as this study
documents outcomes before the licence of any HER2-directed
therapy in this setting.
Pathology
All patients had pathology review by a single specialist breast
pathologist (CAP) working within a pathology laboratory, which is
fully accredited by Clinical Pathology Accreditation UK (CPA UK)
Ltd. Data were recorded as per the National Health Service Breast
Screening Programme Guidelines (NHSBSP) (1995) concerning
tumour grade, tumour size, lymph node (LN) status and presence
of lymphovascular invasion. The Nottingham Prognostic Index
(NPI) was derived from these data (Haybittle et al, 1982; Galea
et al, 1992).
Oestrogen receptor and progesterone receptor
Immunohistochemistry was carried out on diagnostic core
biopsies using primary antibodies for oestrogen receptor (ER)
(clone 6F11, 1:200) and progesterone receptor (PR) (clone 16,
1:800); both from Novocastra Laboratories Ltd, Newcastle Upon
Tyne, UK. Antigen retrieval for ER and PR was carried out using a
microwave pressure vessel followed by processing on a DAKO
TechMate 500 Plus autostainer (Dako, Denmark) with the Dako
REAL detection system (an indirect streptavidin/biotin method
using anti-mouse antibody) and visualised with horseradish
peroxidase and diaminobenzadine. The stained slides were scored
using the ‘quickscore’ method (Detre et al, 1995). Cases scoring
0–3 were regarded as negative from the point of view of endocrine
therapy, whereas cases scoring X4 were regarded as positive.
HER2 assessment
HER2 assessment (IHC and in situ hybridisation) was carried out
in laboratories accredited by CPA UK Ltd and quality assured by
the UK National External Quality Assurance Scheme.
All cases underwent HER2 IHC using the CB11 monoclonal
antibody on the diagnostic core biopsy as previously described
(Purdie et al, 2010) and scored using published criteria (Ellis et al,
2000; Walker et al, 2008). All of those cancers scoring ‘equivocal
(2þ)’ were subjected to HER2 FISH analysis. HER2 FISH was carried
out using the PathVysion HER2 DNA probe kit (Vysis, Abbott
Laboratories, Abbott Park, IL, USA) and assessed as described
using standard criteria (Purdie et al, 2010). Briefly, the ratio of
orange HER2 signals to green alpha satellite CEP17 signals was
calculated and amplification defined as a ratio of X2.00. Cases
scoring IHC negative (0), IHC negative (1þ) or IHC equivocal (2þ)
but FISH negative were classified as HER2 negative and those scoring
IHC equivocal (2þ) and FISH positive or IHC positive (3þ)w e r e
regarded as HER2 positive.
Follow-up
Follow-up data were obtained from the Cancer Centre breast
oncology database. Where necessary, these data were backed up by
contact with the patient’s general medical practitioner or the
registrar of deaths. Because of the stable nature of this population,
complete follow-up data were obtained for all 776 patients who
underwent surgery. In the case of patients who died, the date and
the cause of death was recorded. All deaths that were not
attributable to breast cancer were censored at the date of death.
For those patients who developed recurrence during follow-up, the
date of first recurrence was recorded along with the site of relapse;
this being designated as local, regional or distant. Accordingly, the
primary end points were breast cancer-specific OS and breast
cancer-specific DFS.
Statistical analysis
All associations for 2 2 tables were carried out using a two-sided
Fisher’s Exact Test. For 3 2 tables a chi-squared (w
2) test with
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(ER, PR, HER2) were carried out on the diagnostic core biopsies, it
was possible to test for associations between these parameters for
all tumours undergoing biopsy. The pathological data on tumour
grade, size, lymphovascular invasion, LN status and NPI can only
be obtained from the surgical resection specimens, in which the
entire tumour and LNs can be examined. These data are therefore
confined to patients undergoing surgery. The planned subgroup
analyses included these conventional pathological and hormone
receptor expression parameters.
Survival analysis was carried out by Kaplan–Meier survival
curves analyzed by the log-rank test. Multivariate analysis was
carried out using Cox’s regression.
Multiple tumours
In the 39 patients who had multiple tumours and underwent
surgery, the cancer with the highest NPI was used as the index
lesion for the survival analysis as this tumour was the biologically
most aggressive. In every case the tumour producing the highest
NPI was also the tumour with the highest pathological grade.
Furthermore, in all of the patients who had multiple tumours,
one of which was HER2þ, the HER2þ tumour was also the
highest-grade tumour and the tumour with the highest NPI.
RESULTS
Study population
A total of 920 female patients, mean age 61.7 years (range 25.8–96.9),
diagnosed with invasive breast cancer between 1 June 2000 and
30 June 2003 had 965 tumours (41 of the patients had two or more
cancers) (Figure 1). Fifty five patients (6.0%) only had a cytological
diagnosis of malignancy on fine needle aspirate and no histological
(biopsy) diagnosis, as co-morbidity or advanced disease at presenta-
tion precluded surgery. The remaining 865 (94.0%) patients under-
went core biopsy of the primary breast tumour for ER, PR and HER2
analysis. In all, 89 of the 865 patients only had a core biopsy and no
surgery because of co-morbidities or advanced disease at presenta-
tion. Overall 776 of the 865 patients underwent surgical resection
with median duration of follow-up 6.02 years (range 63–100 months)
and the pathological dataset included tumour size, tumour grade,
presence of lymphovascular invasion (LVI), LN status and NPI.
All of the patients in this study who had ERþ tumours were
prescribed endocrine therapy. At the time of this study this was
tamoxifen. Chemotherapy (predominantly anthracycline based)
was administered to 26.2% of the patients in this study with
a significantly higher proportion in HER2þ patients than in the
HER2– patients (45.7 vs 23.2% respectively, Po0.0001). In the
node-negative group, this trend continued with 26.4% of HER2þ
and 9.3% of HER2– patients being given chemotherapy (Po0.001).
Pathology
The distribution of pathological parameters (Supplementary Table
1) showed the proportions that would be expected for a population
which, in 2000–2003, was predominantly symptomatic (82%) in
the presentation (Elston, 1984; Elston and Ellis, 1991; Galea et al,
1992). The Kaplan–Meier plots for survival confirmed that, as
expected, tumour grade (Po0.001), LN status (Po0.001), NPI
(Po0.001), ER status (Po0.001) and PR status (Po0.001) were all
predictive of OS and DFS (data not shown). Of the 910 cancers
biopsied, 81.1% were ERþ and 69.6% PRþ.
HER2 status
The median age at diagnosis was not significantly different for
patients with HER2þ (59.4 years) vs HER2– (61.8 years) cancers
(P¼0.29, Mann–Whitney U-test) with no significant difference in
the frequency of HER2 positivity by age decile (20–90). The results
of the HER2 analysis (Table 1) showed that 121 out of 909 (13.3%)
of the cancers in this unselected population were HER2þ and
that 105 out of 776 (13.5%) patients had a HER2þ cancer
(Table 2). HER2 positivity was associated with higher tumour
grade, node positivity, higher NPI and the presence of LVI (Table 2
and Supplementary Table 2). Furthermore, HER2 status was
associated with disease stage with 10.1% of stage I, 13.9% of stage
II and 22.0% of stage III disease being HER2þ (P¼0.006,
X
2¼10.27, df 2, data not shown). Although there was a negative
association between HER2 status and ER and PR expression,
because most of the cancers were ERþ (81.1%), a majority
(57.0%) of HER2þ cancers were also ERþ (Table 3).
Operative series
776 patients
(819 cancersa)
Patient cohort
920 patients
(965 cancers)
Biopsy series
865 patients
(910 cancers)
FNA only
55 patients
(55 cancers)
Mastectomy
448 patients
(487 cancers)
Conservation
328 patients
(332 cancers)
Tumour grade, size, LVI,
nodal status, NPI, ER,
PR, HER2 and survival.
ER, PR and HER2
Core biopsy only
89 patients
(91 cancersb)
Figure 1 CONSORT diagram of patient and tumour groups.
a35
patients had 2 tumours, 4 patients had 3 tumours.
bTwo patients in this
group had two tumours, each. HER2, human epidermal growth factor
receptor 2; LN, lymph node.
Table 1 HER2 characteristics of all cancers in biopsy series
HER2 characteristics (IHC) N % N %
Negative (0) 254 27.9
Negative (1+) 455 50.1 788 86.7
Equivocal (2+) FISH– 79 8.7
Equivocal (2+) FISH+ 50 5.5 121 13.3
Positive (3+) 71 7.8
Total 909
a 100.0 909
a 100.0
Abbreviations: FISH¼fluorescent in situ hybridization; HER2¼human epidermal
growth factor receptor 2; IHC¼immunohistochemistry. HER2 characteristics of the
910 breast cancers in the biopsy series.
aNo HER2 status was available for one cancer
(IHC ‘equivocal 2+’ but insufficient tissue for FISH analysis).
HER2 status in breast cancer: a population-based study
CA Purdie et al
477
British Journal of Cancer (2010) 103(4), 475–481 & 2010 Cancer Research UK
C
l
i
n
i
c
a
l
S
t
u
d
i
e
sSurvival
Follow-up data for overall (breast cancer specific) and disease
(relapse) free survival were obtained for all 776 patients (100%)
who underwent surgery (Table 4). HER2 positive status was
associated with worse OS (log-rank test X
2¼8.027, df 1,
P¼0.0046) but HER2 status was not associated with prognosis
by subgroup analysis for age at diagnosis, tumour grade or NPI
group (data not shown). HER2 status was significantly associated
with worse survival in LNþ patients (log-rank test X
2¼6.571, df
1, P¼0.0104; Figure 2A) but not in the LN– group (log-rank test
X
2¼0.012, df 1, P¼0.912; Figure 2B). In patients with ERþ
cancer, HER2 status was associated with a worse prognosis (log-
rank test X
2¼7.465, df 1, P¼0.0063; Figure 2C), whereas for the
ER– group, HER2 positivity was not associated with a worse
prognosis (log-rank test X
2¼1.379, df 1, P¼0.240; Figure 2D).
Multivariate analysis using Cox’s regression showed that HER2
status was not an independent prognostic variable in this
population-based study when assessed along with the known
prognostic predictors of tumour grade, size, LN status and ER
(Table 5).
DISCUSSION
The patients and cancers in this study represent, uniquely, an
unselected population of every patient who presented to a single
geographically distinct cancer centre over a 3-year period. There
was no selection bias on the basis of tumour size, grade, nodal
status or disease stage and specimen processing, pathology review,
IHC and FISH were tightly controlled.
The pathological parameters of the cancers in this study
(tumour grade, tumour size and node status) were comparable
with those in other studies (Elston, 1984; Elston and Ellis, 1991)
and were associated with clinical outcome in the way that would be
anticipated from previous published work (Galea et al, 1992). This
indicates that the pathological assessment for the cohort presented
is consistent with reported series (Elston, 1984; Elston and Ellis,
1991; Galea et al, 1992) and confirms the representative nature of
the population studied.
Although there remains ongoing debate about the relative merits
of IHC and FISH testing for routine clinical practice (Sauter et al,
2009) and whether further refinement of HER2 testing such as
phospho HER2 analyses (Frogne et al, 2009) will add additional
value remains to be seen, this series was based on current
guidelines for HER2 testing (Ellis et al, 2000; Walker et al, 2008).
The proportion of breast cancers in this series that were HER2þ
was 13.3% overall with 13.5% of the patients undergoing surgery
having a HER2þ cancer. These data are in keeping with national
(UK) HER2 audit figures (Walker et al, 2008) but lower than most
previously published series (Slamon et al, 1989; Seshadri et al,
Table 2 Clinical and pathological associations of patients by HER2 status
HER2– HER2+ Total
N (%) N (%) N (%) P
a
Screening 125 (18.6) 14 (13.3) 139 (17.9)
Symptomatic 546 (81.4) 91 (86.7) 637 (82.1)
Total 671 (100.0) 105 (100.0) 776 (100.0) 0.22
Grade 1 143 (21.4) 1 (1.0) 144 (18.6)
Grade 2 298 (44.5) 21 (20.0) 319 (41.2)
Grade 3 228 (34.1) 83 (79.0) 311 (40.2)
Total 669 (100.0) 105 (100.0) 774 (100.0)
b 10
 12
Node negative 411 (61.7) 53 (50.5) 464 (60.2)
Node positive (1–3) 190 (28.5) 31 (29.5) 221 (28.7)
Node positive (4+) 65 (9.8) 21 (20.0) 86 (11.1)
Total 666 (100.0) 105 (100.0) 771 (100.0)
c 0.009
GPG (2.10–3.40)
d 266 (40.1) 12 (11.4) 278 (36.2)
MPG (3.41–5.40)
d 265 (39.9) 52 (49.5) 317 (41.2)
PPG (45.40)
d 133 (20.0) 41 (39.1) 174 (22.6)
Total 664 (100.0) 105 (100.0) 769 (100.0)
b,c 10
 8
LVI absent 510 (76.0) 64 (61.0) 574 (74.0)
LVI present 161 (24.0) 41 (39.0) 202 (26.0)
Total 671 (100.0) 105 (100.0) 776 (100.0) 0.0018
ER+ 565 (84.2) 58 (55.2) 623 (80.3)
ER– 106 (15.8) 47 (44.8) 153 (19.7)
Total 671 (100.0) 105 (100.0) 776 (100.0) 10
 10
PR+ 492 (73.3) 42 (40.0) 534 (68.8)
PR– 179 (26.7) 63 (60.0) 242 (31.2)
Total 671 (100.0) 105 (100.0) 776 (100.0) 10
 10
Abbreviations: ER¼oestrogen receptor; FISH¼fluorescent in situ hybridization;
GPG¼good prognostic group; HER2¼human epidermal growth factor receptor 2;
LVI¼lymphovascular invasion; MPG¼moderate prognostic group; PPG¼poor
prognostic group; PR¼progesterone receptor. HER2 characteristics of the 776
surgically treated patients.
aw
2 test with Yates’ correction for 3x2 tables, two-sided
Fisher’s exact test for 2x2 tables.
bTwo cancers showed a pCR to neo-adjuvant
chemotherapy.
cFive cancers had no axillary nodes as a result of previous axillary
surgery.
dNottingham Prognostic Index.
Table 3 Association of HER2 status with hormone receptor expression
HER2– HER2+ Total (%)
N (%) N (%) N (%) P
a
ER+ 668 (84.8) 69 (57.0) 737 (81.1)
ER  120 (15.2) 52 (43.0) 172 (18.9)
Total 788 (100.0) 121 (100.0) 909 (100.0)
b o10
 8
PR+ 582 (73.9) 50 (41.3) 632 (69.5)
PR  206 (26.1) 71 (58.7) 277 (30.5)
Total 788 (100.0) 121 (100.0) 909 (100.0)
b o10
 8
Abbreviations: ER¼oestrogen receptor; HER2¼human epidermal growth factor
receptor 2; PR¼progesterone receptor. HER2 characteristics of 910 biopsied cancers
(core biopsies and surgical resections).
aTwo-sided Fisher’s exact test.
bOne cancer
had insufficient tissue for HER2 fluorescent in situ hybridization analysis.
Table 4 Outcome at 5 years
5-Year
DFS (%)
5-Year
OS (%) v
2 P
Hazard
ratio
All cases
HER2– 85.5 88.2 8.027 0.0046 1.881
HER2+ 73.0 78.8
Lymph node negative
HER2– 91.6 93.8 0.012 0.912 1.061
HER2+ 87.6 95.8
Lymph node positive
HER2– 75.9 79.7 6.571 0.010 1.903
HER2+ 58.7 62.3
ER–
HER2– 58.5 62.3 1.379 0.240 0.698
HER2+ 67.0 68.9
ER+
HER2– 90.4 93.0 7.465 0.006 2.434
HER2+ 77.8 86.9
Abbreviations: ER¼oestrogen receptor; DFS¼disease-free survival; HER2¼human
epidermal growth factor receptor 2; OS¼overall survival; PR¼progesterone
receptor. DFS and OS at 5 years were reported for 776 patients undergoing
primary surgical therapy for breast cancer. Hazard ratio, w
2 and P-value for risk of
death. Data derived from Kaplan–Meier analysis.
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s1993; Press et al, 1997; Koeppen et al, 2001; Ellis et al, 2005; Crowe
et al, 2006; Park et al, 2006), in which case selection for larger
tumours to allow tumour sampling may have been used. This study
includes 18% of cancers originating from a screening population,
in which the preponderance of small, node-negative cancers may
have a lower frequency of HER2 positivity (Chia et al, 2008; Frogne
et al, 2009; Tovey et al, 2009). It is proposed that 13.3% is an
accurate assessment of the prevalence of HER2þ breast cancer in
a Western population with a high incidence of breast cancer.
The data show a clear and strong association between HER2
positivity and other poor prognostic features (Table 2), in keeping
with previous studies (Seshadri et al, 1993), and the same
associations between HER2 and tumour grade, nodal metastasis,
lymphovascular invasion, ER and PR expression whether analysis
was conducted by individual tumour or by patient. HER2 positivity
was not, however, an independent prognostic factor on Cox’s
regression analysis. We found no association between HER2 status
and age at presentation. Data from the selected populations
suggest that HER2 positivity is seen more commonly in younger
women (Gonzalez-Angulo et al, 2009), whereas others do not find
this association (Chia et al, 2008; Tovey et al, 2009). This
population-based study should give the most accurate assessment
of the relationships between age and HER2 status and has failed to
confirm any linkage.
As expected, HER2þ patients had significantly worse OS and
DFS than HER2– women (Slamon et al, 1987; Press et al, 1993).
However, planned subset analysis showed that this was largely
confined to the node-positive and ERþ subgroups. The sig-
nificance of HER2 status in node-negative cancers remains
controversial, confounded by small series, differing methodo-
logies, case selection bias and relatively short follow-up periods
(Press et al, 1993; Seshadri et al, 1993; Ravdin and Chamness, 1995;
Mirza et al, 2002) or series pre-selected for good prognostic
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58 0 1 0 6 9 78 37 06 2 1 19 40
20 47 46 38 33 32 15 20 28
Figure 2 Kaplan–Meier plots of overall survival for HER2 status, (A) lymph node positive, (B) lymph node negative. (C)E Rþ,( D) ER–. HER2, human
epidermal growth factor receptor 2; ER, oestrogen receptor.
Table 5 Cox’s regression analysis (survival)
Breast cancer death
Predictor b P RR (95% CI)
ER  1.25 o0.001 0.28 (0.19–0.44)
LN status 0.95 o0.001 2.59 (1.68–3.99)
Tumour size 0.82 o0.001 2.27 (1.66–3.09)
Tumour grade 3 0.71 0.006 2.03 (1.23–3.35)
HER2 status o0.01 0.999 1.00 (0.63–1.59)
Abbreviations: CI¼confidence intervals; ER¼oestrogen receptor; LN¼lymph
node; RR¼relative risk. Variables were analysed by Cox’s proportional hazards
regression model. Total number of cases 768 with 110 events. G-statistic
w
2¼153.57, df¼5, Po0.0001. ER status, positive vs negative; LN status, positive
vs negative; tumour size, T1 vs T2 vs T3; tumour grade 3, grade 3 vs grades 1 and 2;
HER2 status, positive vs negative.
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sfeatures (Chia et al, 2008; Curigliano et al, 2009; Gonzalez-Angulo
et al, 2009; Tovey et al, 2009); issues abrogated in the 776 surgical
patients with a median follow-up of 6.02 years examined in
this study. These findings indicate that the survival deficit for
HER2þ cases is largely confined to node-positive cancers.
However, trastuzumab is effective in the node-negative subgroup
(Piccart-Gebhart et al, 2005), raising the intriguing possibility that
the prognosis of such HER2þ patients may be therapeutically
improved to exceed that of HER2– patients at least in the node-
negative group.
Chemotherapy was given to 26.2% of the patients in this study.
However, a significant difference in chemotherapy treatment with
regard to HER2 status was seen with 45.7% of HER2þ and 23.2%
HER2– patients receiving chemotherapy (Po0.0001). This signi-
ficant difference was also present in the node-negative group
with 25.0% of HER2þ and 7.5% of HER2– patients being given
adjuvant chemotherapy (Po0.001). At the time of treatment
planning for the patients in this study, HER2 status was not being
used as a factor in the process as this study predates the
publication of the adjuvant trastuzumab clinical trials (Piccart-
Gebhart et al, 2005; Romond et al, 2005; Smith et al, 2007; Perez
and Baweja, 2008). Therefore, the increased use of chemotherapy
in the HER2þ patients in this study reflects the association of
HER2 positivity with other markers of tumour aggressiveness such
as higher grade, higher stage and ER negativity (Tables 2 and 3).
Thus, despite being more likely to have received adjuvant
chemotherapy, the HER2þ patients had a worse survival. It is
possible that the increased use of chemotherapy in the HER2þ,
node-negative group could be responsible for improving their
survival to be closer to the HER2–, node-negative group
(Figure 2B). However, as only 43 of 454 node-negative patients
(9.5%) overall received adjuvant chemotherapy, this study is
underpowered to confirm this point.
While this population-based cohort study confirms that
HER2þ cancers have a worse DFS and OS, the proportion of
HER2þ breast cancers (13.3%) in this Caucasian, Western
population is at the lower end of the published range (Slamon
et al, 1989; Seshadri et al, 1993; Press et al, 1997; Koeppen et al,
2001; Ellis et al, 2005; Crowe et al, 2006; Park et al, 2006; Chia et al,
2008; Frogne et al, 2009; Tovey et al, 2009). However, this cohort
analysis also highlights that women with ERþ, HER2þ cancers
(69 out of 909 (7.6%) of all cancers in 58 out of 776 (7.5%) of all
patients) have a significantly worse prognosis than those with
ERþ, HER2– disease. This finding is similar to other studies in
which HER2 status was associated with DFS in ERþ but not ER–
disease even in small, node-negative series (Curigliano et al, 2009),
but different from some others in which the converse was observed
(Chia et al, 2008; Gonzalez-Angulo et al, 2009). However, these
studies were largely confined to specific subgroups of small, node-
negative cancers and looked at relapse-free survival. The strength
of our study lies in the fact that it is population based, has full
follow-up data on all of the patients and looks at OS as well as DFS.
Women with ERþ, HER2þ cancers form a subgroup of
patients for whom therapy targeting HER2 could be particularly
advantageous. As 46.6% of these patients (27 out of 58), were node
negative and standard prognostic indicators such as NPI and
Adjuvant! Online do not currently include HER2 status, the
prognosis of these ERþ/HER2þ patients may be overestimated.
In all, 57% of the HER2þ patients in this series were also ERþ.
Although HER2 status did not influence survival in node-negative
patients in this population-based study, subgroup analysis of the
HERA study has shown that trastuzumab therapy improves DFS in
node-negative, HER2þ disease (Piccart-Gebhart et al, 2005; Smith
et al, 2007). There were only 27 ERþ, HER2þ, LN– patients in
this series (27 out of 771, 3.5%), so it would not be justified to
carry out survival analysis on such a small number of patients. It is
noteworthy that the survival difference between ERþ, HER2þ
and ERþ, HER2– patients only emerged after 3–4 years (Figure 2)
so only longer follow-up of the large adjuvant trials and this series
can be expected to elucidate whether node-negative patients
should receive trastuzumab. It is possible that HER2þ,E R þ,
LN– patients may get further benefit from trastuzumab, which
might improve DFS and OS to above that of HER2–, ERþ,
LN– disease.
Since the population of women reported in this study was
diagnosed (2000–2003), adjuvant therapies directed against HER2
have become part of routine clinical practice. Therapy directed
against HER2 (trastuzumab) can improve outcome in HER2þ
breast cancers as adjuvant therapy along with chemotherapy
(Piccart-Gebhart et al, 2005; Romond et al, 2005; Smith et al, 2007;
Perez and Baweja, 2008), although the duration of follow-up in
most studies is relatively short. Subgroup analysis of cases in the
HERA study showed that trastuzumab is equally effective in both
ERþ and ER– cases (Piccart-Gebhart et al, 2005; Smith et al,
2007). However, guidelines in some countries (SIGN, 2005; Harnett
et al, 2009) stipulate that trastuzumab can only be administered in
the adjuvant setting (outwith clinical trials) to patients who also
receive adjuvant chemotherapy. In our community-based series, a
majority of HER2þ patients were ERþ (57%) and as their
prognosis could be overestimated on conventional criteria, some
risk being undertreated. They comprised 7.5% of all patients with
operable tumours (Table 2) and nearly half (3.5%) were node
negative. The numbers are thus small but their management needs
to be carefully evaluated to ensure that they are not undertreated.
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